Welgus Howard G. sold $133K of ARQT
Welgus Howard G. sold 4,728 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $28.16 ($0.13M total) on 2026-11-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director’s open-market sale under a pre-arranged 10b5-1 plan is typically treated as routine compliance rather than a direct fundamental catalyst.
Market read
Traders may monitor insider-flow sentiment, but the 10b5-1 structure reduces the likelihood of a material price catalyst.
What to watch
The article provides only the sale details; it does not state whether there were concurrent buys, changes in business outlook, or broader insider activity trends.
Background
The article is a SEC Form 4 insider transaction report for Arcutis Biotherapeutics, Inc. (ARQT).
Ticker impact
Director Welgus Howard G. sold 4,728 shares in an open-market transaction on 2026-11-16 under a pre-arranged 10b5-1 plan.
Likely limited, with any reaction more sentiment-driven than fundamental.
The filing is a Form 4 insider sale with 10b5-1 pre-arrangement, and it does not include new operating, regulatory, or financial guidance.
Market effects
No clear sector read-through from a single director 10b5-1 sale.
None.
None.
Counterpoint
Even with 10b5-1, repeated insider selling can be interpreted as reduced confidence, especially if paired with other negative signals not mentioned here.
Key entities
- issuerArcutis Biotherapeutics, Inc.
US-listed biotherapeutics company subject of the Form 4 insider sale disclosure.
- insiderWelgus Howard G.
Director who sold 4,728 shares on 2026-11-16 under a 10b5-1 plan.

